Goat Mastitis: Milk Sampling, Treatment Monitoring, and Herd Prevention

At a Glance

Scope and Reader Context

This article provides veterinarians and goat producers with a practical framework for diagnosing and managing mastitis in goats. Mastitis in goats presents unique challenges compared to dairy cattle, including differences in udder anatomy, milk composition, and pathogen profiles. The approach covers clinical and subclinical mastitis, aseptic milk sampling technique, culture and sensitivity interpretation, treatment protocols including intramammary and systemic antibiotics with NSAIDs, monitoring cure rates, and herd-level prevention strategies including milking hygiene, dry-off therapy, and culling chronic cases. The guidance is based on peer-reviewed evidence and established veterinary practice standards from sources including the Merck Veterinary Manual, the World Organisation for Animal Health, and published research in journals such as the Journal of Dairy Science and BMC Microbiology.

Clinical and Subclinical Mastitis in Goats

Distinguishing Clinical from Subclinical Disease

Clinical mastitis in goats presents with visible udder abnormalities including swelling, heat, pain, redness, and milk changes such as clots, flakes, or watery appearance. Systemic signs may include fever, anorexia, and depression. Gangrenous mastitis, particularly from coliform bacteria, can cause rapid tissue necrosis and toxemia as described in the literature on gangrenous caprine coliform mastitis (Small Ruminant Research, 1994). Subclinical mastitis shows no visible udder or milk changes but is detected through diagnostic testing. The California Mastitis Test (CMT) and somatic cell count (SCC) are primary screening tools. Research on Etawa breeding goats found that 50% of milk samples showed subclinical mastitis level III and 36.7% showed level II based on CMT results (Buletin Veteriner Udayana, 2024). This high prevalence underscores the importance of routine screening.

Pathogen Profiles in Caprine Mastitis

The major mastitis pathogens in goats include Staphylococcus aureus, coagulase-negative staphylococci (CNS), Streptococcus spp., Escherichia coli, Pseudomonas spp., and Mycoplasma spp. The role of intramammary pathogens in dairy goats has been documented in the literature (Livestock Production Science, 2003). S. aureus is a contagious pathogen that can cause persistent infections. Research on extramammary colonization found that 51.7% of goats had S. aureus colonization at extramammary sites, with the nares colonized most frequently at 45% (Pathogens, 2023). This finding has important implications for transmission control. Coagulase-negative staphylococci are common in subclinical mastitis and may carry virulence factors as described in studies on virulence factors genes of Staphylococcus spp. isolated from caprine subclinical mastitis (Microbial Pathogenesis, 2015). Pseudomonas species have been isolated from teat skin swabs during the dry period, suggesting environmental sources (Alexandria Journal of Veterinary Sciences, 2020).

Risk Factors for Mastitis Development

Risk factors for caprine mastitis include parity, stage of lactation, udder conformation, milking hygiene, and environmental conditions. Research on occurrence, pathogens and risk factors for subclinical mastitis in dairy goats has identified management practices that influence infection risk (Arquivo Brasileiro De Medicina Veterinaria E Zootecnia, 2018). Dry period infections are particularly important, as bacterial species isolated during the dry period can persist into lactation. A study found that coagulase-positive staphylococci, CNS, Streptococcus uberis, E. coli, and Pseudomonas species were isolated from dry period secretion samples, and these same pathogens appeared at varying incidences during the first six weeks of lactation (Alexandria Journal of Veterinary Sciences, 2020). Caprine arthritis-encephalitis virus (CAEV) can also cause indurative mastitis and should be considered in herds with chronic udder fibrosis, as noted in literature on ovine progressive pneumonia and caprine arthritis-encephalitis (Veterinary Clinics of North America Food Animal Practice, 1990).

Aseptic Milk Sampling Technique

Equipment and Preparation

Proper aseptic milk sampling is essential for accurate culture results. Required equipment includes sterile collection tubes, 70% isopropyl alcohol swabs or cotton balls, sterile gloves, and a cooler with ice packs for transport. The sampling area should be clean and well-lit. Teats must be dry and free of visible dirt before sampling. Pre-dipping with an approved teat disinfectant and allowing appropriate contact time reduces contamination risk.

Step-by-Step Sampling Protocol

1. Restrain the doe safely in a stanchion or with a handler.
2. Wear clean disposable gloves.
3. Discard first three streams of milk from each teat to flush the teat canal.
4. Clean the teat end thoroughly with a 70% alcohol swab using a circular motion from center outward.
5. Allow the alcohol to dry completely (approximately 30 seconds).
6. Hold the sterile tube horizontally to avoid contamination from the hand.
7. Collect 5-10 mL of milk directly into the sterile tube without touching the teat end to the tube rim.
8. Cap the tube immediately.
9. Label the tube with goat ID, date, and teat (left or right).
10. Place the sample in a cooler with ice packs for transport to the laboratory.

Sample Handling and Transport

Milk samples should be refrigerated at 4°C if processing within 24 hours. For longer storage, freeze at -20°C, though this may reduce recovery of some pathogens. Transport samples to the diagnostic laboratory within 24 hours of collection. Delayed transport can lead to overgrowth of contaminants or death of fastidious organisms. The Merck Veterinary Manual provides additional guidance on sample handling for mastitis diagnosis.

Common Sampling Errors

Common errors that compromise culture results include inadequate teat end disinfection, touching the tube rim to the teat, collecting insufficient volume, failing to discard foremilk, and using non-sterile tubes. Contaminated samples may show growth of multiple organisms or environmental contaminants such as Bacillus spp. or coliforms. If contamination is suspected, repeat sampling after 48 hours.

Culture and Sensitivity Testing

Laboratory Submission

Submit milk samples to a veterinary diagnostic laboratory for aerobic culture and antimicrobial susceptibility testing. Request identification of all significant isolates and quantitative culture if indicated. The laboratory should report colony counts and identify pathogens to species level when clinically relevant. For S. aureus, request spa genotyping if available, as this can help track transmission patterns within the herd as described in research on multilocus sequence analysis of S. aureus isolates from goats with persistent mastitis (Scientific Reports, 2021).

Interpreting Culture Results

Interpret culture results based on colony count and pathogen significance. Pure growth of a known mastitis pathogen at >100 CFU/mL is generally considered significant. Mixed growth of three or more organisms may indicate contamination. Coagulase-negative staphylococci are common in subclinical mastitis but may also be contaminants. S. aureus is always significant when isolated from milk. Pseudomonas species indicate environmental contamination and may be associated with water quality issues. Mycoplasma species require special culture media and should be requested if clinical signs suggest mycoplasmal mastitis.

Antimicrobial Susceptibility Testing

Antimicrobial susceptibility testing (AST) guides treatment selection. The laboratory will report minimum inhibitory concentrations (MICs) or disk diffusion results with interpretations of susceptible, intermediate, or resistant. Use AST results to select antibiotics with the narrowest spectrum appropriate for the pathogen. Avoid using antibiotics classified as critically important for human medicine when alternatives exist. The World Organisation for Animal Health provides guidance on prudent use of antimicrobials in animals.

Limitations of Culture and Sensitivity

Culture results have limitations. False negatives can occur with low-level shedding, intermittent shedding, or fastidious organisms. Prior antibiotic treatment can suppress bacterial growth. Sensitivity testing is performed in vitro and may not predict in vivo response due to factors such as drug distribution in the udder, milk pH, and host immune response. Some pathogens, particularly S. aureus, may show in vitro susceptibility but fail to respond to treatment due to biofilm formation or intracellular survival as described in research on S. aureus profiles before and after treatment with enrofloxacin (BMC Microbiology, 2020).

Treatment Protocols for Goat Mastitis

Intramammary Antibiotic Therapy

Intramammary (IMM) antibiotic therapy delivers high drug concentrations directly to the infected udder tissue. Select IMM products labeled for use in lactating goats when available. For extralabel use, follow veterinary prescription requirements and observe extended withdrawal periods. Administer IMM therapy after complete milking out of the affected half. Clean the teat end with alcohol before infusion. Insert the cannula only partially into the teat canal to reduce trauma. Massage the drug upward into the gland after infusion. Treatment duration is typically 3-5 consecutive milkings for acute cases, but chronic infections may require longer courses.

Systemic Antibiotic Therapy

Systemic antibiotic therapy is indicated for severe clinical mastitis with systemic signs, gangrenous mastitis, or when IMM therapy alone is insufficient. Systemic antibiotics distribute to udder tissue through the bloodstream. Choose drugs with good udder penetration and activity against the identified pathogen. Common systemic antibiotics used in goats include oxytetracycline, ceftiofur, and florfenicol, but selection should be based on culture and sensitivity results. Administer systemic antibiotics according to label directions or veterinary prescription. Monitor for adverse reactions, particularly in goats with compromised renal or hepatic function.

Non-Steroidal Anti-Inflammatory Drugs

NSAIDs are important adjunctive therapy for mastitis. They reduce inflammation, pain, and fever, and may improve milk let-down. Flunixin meglumine and meloxicam are commonly used in goats. Administer NSAIDs at the time of diagnosis and continue for 1-3 days based on clinical response. Monitor for gastrointestinal and renal side effects, particularly in dehydrated or hypovolemic animals. NSAIDs should not be used concurrently with corticosteroids due to increased risk of gastrointestinal ulceration.

Supportive Care

Supportive care includes frequent milking out of the affected half (every 4-6 hours for acute cases), fluid therapy for dehydrated animals, and nutritional support. For gangrenous mastitis, surgical debridement or amputation of the affected teat or udder half may be necessary. Provide clean, dry bedding and separate affected animals from the milking herd. Monitor body temperature, appetite, and udder appearance twice daily during treatment.

Withdrawal Periods

Withdrawal periods for milk and meat must be observed after antibiotic treatment. For drugs labeled for goats, follow label withdrawal times. For extralabel drug use, consult the Food Animal Residue Avoidance Databank (FARAD) or equivalent regulatory body for recommended withdrawal periods. Extended withdrawal periods are required for drugs not labeled for goats. Discard milk from treated animals for the entire withdrawal period plus an additional 24-48 hours to ensure complete clearance. Record all treatments and withdrawal dates in individual animal records.

Monitoring Cure Rates

Defining Cure

Cure is defined as elimination of the infection from the affected udder half. Bacteriological cure is confirmed by negative culture at 14-21 days post-treatment. Clinical cure is resolution of visible signs. Subclinical cure is return to normal SCC or CMT. Cure rates vary by pathogen, with CNS generally showing higher cure rates than S. aureus or Pseudomonas. Research on diagnosis and treatment of subclinical mastitis in early lactation in dairy goats provides data on treatment outcomes (Journal of Dairy Science, 2010).

Post-Treatment Sampling Protocol

Collect milk samples for culture 14-21 days after completion of antibiotic therapy. Use aseptic technique as described above. Submit samples for culture even if clinical signs have resolved, as subclinical infection may persist. For goats that received systemic antibiotics, ensure adequate withdrawal period has passed before sampling for residue testing.

Interpreting Post-Treatment Results

Negative culture at 14-21 days indicates bacteriological cure. Positive culture with the same pathogen indicates treatment failure. Positive culture with a different pathogen indicates a new infection. Persistent infection with S. aureus may require alternative treatment approaches or culling. Research on S. aureus isolates from goats with persistent mastitis after enrofloxacin treatment has shown genetic diversity and potential for antimicrobial resistance development (Scientific Reports, 2021).

Treatment Failure Investigation

When treatment fails, investigate potential causes including incorrect diagnosis, inappropriate antibiotic selection, inadequate dose or duration, poor drug penetration, biofilm formation, or host factors such as chronic fibrosis. Re-culture and perform AST to identify any changes in susceptibility. Consider alternative treatment protocols or culling for chronic cases. Document all treatment failures in herd records for pattern analysis.

Herd-Level Prevention Strategies

Milking Hygiene

Milking hygiene is the cornerstone of mastitis prevention. Implement a consistent milking routine that includes pre-dipping with an approved teat disinfectant, wiping teats dry with individual paper towels, attaching milking units to clean dry teats, and post-dipping after milking. Maintain milking equipment according to manufacturer specifications. Check vacuum levels and pulsation rates monthly. Replace liners according to manufacturer recommendations or at least every 1,500 milkings. The Merck Veterinary Manual provides detailed guidance on milking machine maintenance.

Dry-Off Therapy

Dry-off therapy treats existing infections and prevents new infections during the dry period. Administer dry cow intramammary products to all udder halves at dry-off. Select products with activity against the pathogens present in the herd. Dry-off therapy is particularly important for goats because dry period infections can persist into the next lactation as shown in research on dry period infection and teat skin microflora (Alexandria Journal of Veterinary Sciences, 2020). Monitor does at freshening for clinical mastitis and culture milk samples to assess dry-off therapy effectiveness.

Culling Chronic Cases

Culling chronic mastitis cases reduces the reservoir of infection in the herd. Establish culling criteria based on number of treatments, duration of infection, SCC history, and production losses. Does with gangrenous mastitis, chronic S. aureus infection, or persistently high SCC should be culled. Document culling decisions and reasons in herd records. Replace culled animals with healthy replacements from herds with known mastitis status.

Environmental Management

Environmental management reduces exposure to environmental pathogens. Provide clean, dry bedding in well-ventilated housing. Clean and disinfect kidding areas between uses. Manage manure to minimize udder contamination. Provide clean water sources and prevent standing water that can harbor Pseudomonas species. Control flies and other vectors that may transmit mastitis pathogens.

Biosecurity

Biosecurity measures prevent introduction of new mastitis pathogens. Quarantine new animals for at least 30 days and test for mastitis before introduction to the milking herd. Test purchased animals for CAEV and other infectious diseases. Use separate milking equipment for infected animals. Implement visitor protocols that prevent contamination of the milking area.

Records and Measurements

Individual Animal Records

Maintain individual animal records for each doe including identification, parity, kidding dates, mastitis history, treatment dates and protocols, culture results, SCC or CMT results, and culling decisions. Record all antibiotic treatments including drug, dose, route, duration, and withdrawal period. Use these records to identify patterns and evaluate treatment effectiveness.

Herd-Level Monitoring

Monitor herd-level mastitis indicators including monthly bulk tank SCC, clinical mastitis incidence rate, subclinical mastitis prevalence, and treatment cure rates. Calculate clinical mastitis incidence as number of new cases per 100 does per month. Calculate subclinical mastitis prevalence as percentage of does with CMT score >2 or SCC >200,000 cells/mL. Track these indicators over time to evaluate prevention program effectiveness.

Somatic Cell Count Monitoring

Somatic cell count monitoring is useful for detecting subclinical mastitis. Goat milk normally has higher SCC than cow milk due to apocrine secretion. Individual goat SCC >1,000,000 cells/mL is generally considered elevated. Bulk tank SCC >750,000 cells/mL indicates herd-level mastitis problems. Use SCC data to identify individual animals for culture and treatment. The California Mastitis Test provides a rapid on-farm screening method that correlates with SCC.

Treatment Records

Record all mastitis treatments in a log that includes goat ID, date of diagnosis, clinical signs, culture results, antibiotic used, dose, route, duration, NSAID use, supportive care, and outcome. Record withdrawal periods and dates when milk can be marketed. Review treatment records quarterly to identify patterns of treatment failure or antimicrobial resistance.

Common Failure Patterns

Inadequate Sampling Technique

Inadequate sampling technique is a common cause of inaccurate culture results. Contaminated samples lead to unnecessary treatment or incorrect antibiotic selection. Train all personnel in aseptic technique and audit sampling procedures periodically. Reject samples that show evidence of contamination.

Inappropriate Antibiotic Selection

Inappropriate antibiotic selection based on clinical signs alone without culture and sensitivity testing leads to treatment failure. Some pathogens, such as Pseudomonas species, are inherently resistant to many antibiotics. S. aureus may develop resistance during treatment as shown in research on S. aureus profiles before and after enrofloxacin treatment (BMC Microbiology, 2020). Always base antibiotic selection on AST results.

Insufficient Treatment Duration

Insufficient treatment duration is a common cause of treatment failure. Short courses of antibiotics may suppress but not eliminate infection, leading to relapse. Chronic infections, particularly with S. aureus, may require extended treatment courses. Follow veterinary recommendations for treatment duration based on pathogen and clinical response.

Failure to Address Environmental Sources

Failure to address environmental sources of infection leads to recurrent mastitis. Pseudomonas species in water sources, contaminated bedding, and dirty housing contribute to new infections. Investigate environmental sources when multiple animals develop mastitis with the same environmental pathogen.

Neglecting Dry Period Management

Neglecting dry period management allows infections to persist and new infections to develop. Dry-off therapy is essential for controlling mastitis in the subsequent lactation. Research has shown that bacterial species isolated during the dry period can appear in milk samples during the first six weeks of lactation (Alexandria Journal of Veterinary Sciences, 2020).

Welfare and Safety Context

Pain Management

Mastitis causes significant pain and distress in affected animals. Pain management is an essential component of treatment. NSAIDs provide analgesia and reduce inflammation. For severe cases, additional analgesia may be required. Observe animals for signs of pain including reluctance to move, decreased appetite, and abnormal posture. The World Organisation for Animal Health emphasizes the importance of animal welfare in livestock production.

Antimicrobial Stewardship

Antimicrobial stewardship is critical to preserve antibiotic effectiveness and prevent resistance. Use antibiotics only when indicated based on culture and sensitivity results. Choose the narrowest spectrum antibiotic effective against the identified pathogen. Avoid routine use of antibiotics classified as critically important for human medicine. Complete the full course of treatment as prescribed. Record all antibiotic use for monitoring and review.

Food Safety

Milk from treated animals must not enter the food supply until withdrawal periods have elapsed. Withdrawal periods for goats may differ from those for cattle due to differences in metabolism. Consult FARAD or equivalent regulatory body for extralabel drug withdrawal recommendations. Test milk for antibiotic residues if there is any doubt about withdrawal period compliance. Contaminated milk can cause allergic reactions in sensitive individuals and contribute to antimicrobial resistance.

Zoonotic Considerations

Some mastitis pathogens have zoonotic potential. S. aureus can cause skin infections and food poisoning. E. coli can cause gastrointestinal illness. Mycobacterium species can cause tuberculosis. Practice good hygiene when handling mastitic milk and udders. Wear gloves when sampling and treating. Discard milk from infected animals appropriately. The World Organisation for Animal Health provides guidance on zoonotic disease prevention.

Professional Escalation Criteria

Urgent Escalation

Refer to a veterinary specialist or diagnostic laboratory immediately for:

• Gangrenous mastitis with systemic toxemia
• Mastitis unresponsive to two courses of appropriate antibiotic therapy
• Suspected mycoplasmal mastitis (requires special culture media)
• Suspected CAEV mastitis (requires serological testing)
• Herd outbreak with >10% of lactating does affected in one week

Routine Escalation

Consult a veterinary specialist or diagnostic laboratory for:

• Persistent subclinical mastitis in multiple animals
• Recurrent mastitis in individual animals
• Antimicrobial resistance patterns requiring alternative treatment protocols
• Herd-level mastitis prevention program evaluation
• Investigation of environmental sources of infection

Diagnostic Laboratory Referral

Submit samples to a veterinary diagnostic laboratory for:

• Culture and sensitivity when treatment is planned
• Identification of unusual pathogens
• Confirmation of mycoplasmal mastitis
• Molecular typing for outbreak investigation
• Antimicrobial resistance surveillance

Decision Framework for Selecting Treatment Duration and Route in Goat Mastitis

Pathogen-Based Treatment Duration Guidelines

Treatment duration for goat mastitis must be matched to the pathogen identified through culture and sensitivity testing. Short courses of 3 to 5 days are appropriate for acute clinical mastitis caused by Escherichia coli or Streptococcus uberis when the animal shows rapid clinical improvement within 48 hours. Extended courses of 7 to 14 days are indicated for Staphylococcus aureus infections, particularly when the infection is chronic or the animal has a history of previous mastitis episodes. Research on S. aureus isolates from goats with persistent mastitis after enrofloxacin treatment has documented genetic diversity and the potential for treatment failure even with extended therapy (Scientific Reports, 2021). Coagulase-negative staphylococci (CNS) infections generally respond to 5 to 7 day courses, though some strains carrying virulence factors may require longer treatment as described in studies on virulence factors genes of Staphylococcus spp. isolated from caprine subclinical mastitis (Microbial Pathogenesis, 2015). Pseudomonas species infections are notoriously difficult to treat and often require 10 to 14 days of systemic therapy combined with intramammary treatment, and even then cure rates are low.

Route of Administration Decision Tree

The choice between intramammary (IMM) therapy alone, systemic therapy alone, or combination therapy depends on the severity of clinical signs, the pathogen involved, and the stage of lactation. Use the following decision framework:

Step 1: Assess clinical severity

• Mild clinical mastitis (localized udder changes, no systemic signs, normal appetite and temperature): IMM therapy alone is appropriate for most pathogens except Pseudomonas and Mycoplasma.
• Moderate clinical mastitis (udder changes plus mild systemic signs such as decreased appetite or mild fever): IMM therapy plus systemic antibiotics is indicated.
• Severe clinical mastitis (marked systemic signs including fever above 40.5 degrees Celsius, anorexia, depression, or toxemia): Systemic antibiotics are primary, with IMM therapy as adjunctive treatment. Gangrenous mastitis requires aggressive systemic therapy and may necessitate surgical intervention as described in the literature on gangrenous caprine coliform mastitis (Small Ruminant Research, 1994).

Step 2: Consider pathogen-specific factors

• S. aureus: Combination IMM and systemic therapy is recommended due to the pathogen's ability to survive intracellularly and form biofilms. Research on S. aureus profiles before and after treatment with enrofloxacin (BMC Microbiology, 2020) has shown that isolates can persist despite treatment, supporting the need for aggressive initial therapy.
• Pseudomonas species: Systemic therapy is primary, IMM therapy alone is rarely effective. Address environmental sources simultaneously.
• E. coli: IMM therapy alone is often sufficient for mild cases, but systemic therapy should be added if systemic signs are present.
• CNS: IMM therapy alone is usually adequate.
• Mycoplasma species: Systemic therapy with appropriate antibiotics (tetracyclines or tylosin) is required, IMM therapy is not effective.

Step 3: Evaluate lactation stage and production goals

• Early lactation (first 30 days): Use IMM therapy cautiously as the udder is more susceptible to trauma from cannula insertion. Systemic therapy may be preferred for moderate to severe cases.
• Mid to late lactation: IMM therapy is well tolerated. Consider dry-off therapy timing if the doe is within 60 days of dry-off.
• Dry period: Use dry cow intramammary products specifically formulated for extended release. Systemic therapy is not typically needed unless clinical mastitis develops during the dry period.

NSAID Selection and Dosing Considerations

Non-steroidal anti-inflammatory drugs (NSAIDs) are essential adjunctive therapy for all cases of clinical mastitis. Flunixin meglumine provides rapid onset of action and is preferred for acute severe cases with systemic signs. Meloxicam has a longer duration of action and is suitable for mild to moderate cases requiring 2 to 3 days of therapy. Administer the first dose at the time of diagnosis. Repeat dosing should be based on clinical response and the specific drug's label duration. Monitor for signs of gastrointestinal distress, reduced appetite, or dark feces which may indicate gastrointestinal ulceration. NSAIDs should not be administered to dehydrated animals until fluid therapy has been initiated. The Merck Veterinary Manual provides dosing guidelines for NSAIDs in goats.

Treatment Monitoring Protocol with Defined Decision Points

Establish a structured monitoring protocol with clear decision points to avoid prolonged ineffective treatment. Use the following schedule:

Day 1 (Treatment initiation)

• Record baseline temperature, udder appearance, milk appearance, and appetite.
• Administer first dose of antibiotic and NSAID.
• Milk out affected half completely every 6 to 8 hours for the first 24 hours.

Day 2 (24-hour reassessment)

• Reassess temperature, udder swelling, milk appearance, and appetite.
• If temperature has normalized and udder swelling is reduced, continue current treatment plan.
• If no improvement or worsening, re-evaluate diagnosis. Consider re-culture if initial culture was not performed. Add systemic therapy if only IMM therapy was used initially.
• If gangrenous changes are progressing, escalate to veterinary surgical evaluation.

Day 3 (48-hour reassessment)

• If clinical signs have resolved, continue antibiotics for the planned duration. NSAIDs can be discontinued if inflammation is minimal.
• If clinical signs are improved but not resolved, continue treatment and reassess on day 5.
• If no improvement, discontinue current antibiotic and re-culture. Consider that the pathogen may be resistant or that a different pathogen is involved.

Day 7 (End of short-course therapy)

• For acute cases treated with 3 to 5 day courses, discontinue antibiotics if clinical signs have resolved.
• Collect milk sample for culture 14 to 21 days after the last antibiotic dose to confirm bacteriological cure.

Day 14 (End of extended-course therapy)

• For chronic or S. aureus cases treated with 10 to 14 day courses, discontinue antibiotics if clinical signs have resolved.
• Collect milk sample for culture 14 to 21 days after the last antibiotic dose.

Record System for Treatment Outcomes

Maintain a standardized treatment record for each mastitis case to track outcomes and identify patterns of treatment failure. Use the following format:

Review treatment records quarterly to calculate cure rates by pathogen. A herd-level cure rate below 70% for CNS or below 50% for S. aureus indicates a need to review treatment protocols and consider alternative approaches.

Troubleshooting Persistent or Recurrent Mastitis

When a doe presents with mastitis that does not respond to initial treatment or recurs after apparent cure, follow this systematic troubleshooting approach:

Step 1: Confirm the diagnosis

• Re-culture the affected udder half using aseptic technique.
• Request quantitative culture to differentiate true infection from contamination.
• If the same pathogen is isolated, request repeat AST to identify any changes in susceptibility.
• If a different pathogen is isolated, the original infection may have resolved and a new infection has occurred.

Step 2: Investigate treatment factors

• Verify that the correct dose was administered. Goats require weight-based dosing, and underdosing is common.
• Confirm that the full course of treatment was completed. Shortened courses are a frequent cause of treatment failure.
• Check that IMM therapy was administered correctly. Partial insertion of the cannula and massage after infusion improve drug distribution.
• Evaluate whether the antibiotic selected has adequate activity against the pathogen in the udder environment. Some antibiotics are inhibited by milk pH or protein binding.

Step 3: Assess host factors

• Chronic fibrosis in the udder reduces drug penetration and blood flow. Does with palpable fibrosis have lower cure rates.
• Advanced age and high parity are associated with reduced immune response and lower cure rates.
• Concurrent disease, including CAEV infection, can impair the doe's ability to clear infection. Literature on ovine progressive pneumonia and caprine arthritis-encephalitis (Veterinary Clinics of North America Food Animal Practice, 1990) describes the association between lentiviral infections and chronic udder disease.

Step 4: Evaluate herd-level factors

• If multiple does have persistent or recurrent mastitis with the same pathogen, investigate environmental sources.
• For Pseudomonas species, test water sources including drinking water, wash water, and milking equipment rinse water.
• For S. aureus, consider extramammary colonization as a source of reinfection. Research has shown that 51.7% of goats had S. aureus colonization at extramammary sites, with the nares colonized most frequently at 45% (Pathogens, 2023). This finding suggests that intervention measures aimed solely at preventing transmission from infected udder glands may be insufficient.
• For E. coli, evaluate bedding hygiene and manure management.

Step 5: Make a decision

• If the doe has had two treatment failures with appropriate antibiotics based on AST, culling should be strongly considered.
• If the doe has recurrent mastitis with different pathogens, evaluate overall management and hygiene practices.
• If the doe has chronic subclinical mastitis with persistently high SCC but no clinical signs, consider culling if she is not a high-producing animal.

Comparison of Intramammary and Systemic Therapy for Common Pathogens

Cure rates are estimates based on published literature including diagnosis and treatment of subclinical mastitis in early lactation in dairy goats (Journal of Dairy Science, 2010) and mastitis of sheep and goats (The Veterinary Clinics of North America. Food Animal Practice, 2001). Actual cure rates vary by herd, pathogen strain, and individual animal factors.

When to Transition from Treatment to Culling

Establish clear criteria for transitioning from treatment to culling to avoid prolonged ineffective therapy and unnecessary antibiotic use. Culling should be considered when:

• The doe has failed to respond to two courses of appropriate antibiotic therapy based on culture and sensitivity results.
• The doe has gangrenous mastitis affecting more than one teat or the entire udder half.
• The doe has chronic S. aureus infection with persistently positive cultures despite treatment.
• The doe has a somatic cell count consistently above 1,500,000 cells/mL for more than two months despite treatment.
• The doe has recurrent clinical mastitis (three or more episodes in one lactation).
• The doe has CAEV-associated indurative mastitis with palpable udder fibrosis.

Document the rationale for culling in herd records. Culled animals should be removed from the milking herd and not used as nurse does for kids. The World Organisation for Animal Health emphasizes that culling chronic cases is an important component of herd health management and disease control.

Frequently Asked Questions

What is the difference between clinical and subclinical mastitis in goats?

Clinical mastitis shows visible signs including udder swelling, heat, pain, redness, and abnormal milk such as clots, flakes, or watery appearance. Systemic signs may include fever and depression. Subclinical mastitis has no visible signs but is detected through diagnostic testing such as the California Mastitis Test, somatic cell count, or bacterial culture. Subclinical mastitis is more common than clinical mastitis and can cause significant production losses. Research on Etawa goats found that 86.7% of milk samples showed subclinical mastitis based on CMT results (Buletin Veteriner Udayana, 2024).

How do I collect a milk sample for culture from a goat?

Collect milk samples using aseptic technique. Wear clean gloves, discard the first three streams of milk, clean the teat end thoroughly with 70% alcohol, allow to dry, collect 5-10 mL of milk directly into a sterile tube without touching the teat to the tube rim, cap immediately, label with goat ID and date, and refrigerate at 4°C for transport to the laboratory within 24 hours. Proper technique is essential to avoid contamination that can lead to inaccurate results.

What are the most common causes of mastitis in goats?

The most common causes of mastitis in goats include Staphylococcus aureus, coagulase-negative staphylococci, Streptococcus species, Escherichia coli, Pseudomonas species, and Mycoplasma species. S. aureus is a contagious pathogen that can cause persistent infections and may colonize extramammary sites such as the nares (Pathogens, 2023). Coagulase-negative staphylococci are common in subclinical mastitis. Environmental pathogens such as E. coli and Pseudomonas are associated with poor hygiene.

How long should I treat a goat with mastitis?

Treatment duration depends on the pathogen, severity of infection, and clinical response. Acute clinical mastitis typically requires 3-5 consecutive milkings of intramammary therapy. Chronic infections, particularly with S. aureus, may require longer courses of 7-14 days. Systemic antibiotics are usually given for 3-5 days for acute cases. Always complete the full course of treatment as prescribed by your veterinarian. Re-culture 14-21 days after treatment to confirm cure.

Can I use cow mastitis products in goats?

Cow mastitis products are often used in goats on an extralabel basis, but this requires a valid veterinarian-client-patient relationship and prescription. Goats metabolize drugs differently than cows, so withdrawal periods may be longer. Consult FARAD or equivalent regulatory body for recommended withdrawal periods. Some cow products may not be effective in goats due to differences in udder physiology and pathogen susceptibility. Always base treatment on culture and sensitivity results.

How do I prevent mastitis in my goat herd?

Prevent mastitis through a comprehensive program including milking hygiene (pre-dipping, post-dipping, clean equipment), dry-off therapy for all does, culling chronic cases, environmental management (clean bedding, ventilation, water quality), biosecurity (quarantine new animals, test for CAEV), and regular monitoring (CMT or SCC, culture). The Merck Veterinary Manual provides detailed guidance on mastitis prevention in dairy animals.

What is the California Mastitis Test and how do I use it in goats?

The California Mastitis Test (CMT) is a rapid on-farm screening test that detects elevated somatic cell counts indicative of mastitis. Mix equal parts milk and CMT reagent in a paddle well, swirl gently, and read the reaction within 15 seconds. Reactions are scored from negative (no gel formation) to trace (slight thickening) to 1+ (distinct gel) to 2+ (strong gel) to 3+ (gel forms a peak). Goat milk normally has higher SCC than cow milk, so interpret results accordingly. Research has shown a significant relationship between CMT and boiling test results for milk quality assessment (Buletin Veteriner Udayana, 2024).

When should I cull a goat with mastitis?

Cull goats with gangrenous mastitis, chronic S. aureus infection unresponsive to two treatment courses, persistently high SCC (>1,000,000 cells/mL) despite treatment, recurrent clinical mastitis, or CAEV-associated indurative mastitis. Culling removes the infection reservoir from the herd and prevents transmission to healthy animals. Document culling decisions and reasons in herd records. Replace culled animals with healthy replacements from herds with known mastitis status.

Related Veterinary Guides

• Transition Cow Management From Dry Off To Freshening
• Veterinary Clinical Methods Procedures Surgical Interventions
• Goat Health Management Vaccination Biosecurity Disease Prevention
• Calving Management For Beef Herds
• Dairy Cow Lameness Prevention And Mobility Scoring

References and Further Reading

• www.acvim.org
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• Mastitis and other diseases of the goat's udder.. Journal of the American Veterinary Medical Association, 1977.
• Profiles of Staphyloccocus aureus isolated from goat persistent mastitis before and after treatment with enrofloxacin.. BMC microbiology, 2020.
• Diagnosis and treatment of subclinical mastitis in early lactation in dairy goats.. Journal of dairy science, 2010.
• Protothecosis in Veterinary Medicine: a minireview.. Letters in applied microbiology, 2023.
• Multilocus sequence analysis reveals genetic diversity in Staphylococcus aureus isolate of goat with mastitis persistent after treatment with enrofloxacin.. Scientific reports, 2021.
• Mastitis of sheep and goats.. The Veterinary clinics of North America. Food animal practice, 2001.
• MILK QUALITY OF ETAWA BREEDING GOATS SEEN FROM CALIFORNIA MASTITIS TEST, ALCOHOL TEST, REDUCTASE TEST, AND BOILING TEST IN RAKA ETAWA FARMING. Buletin Veteriner Udayana, 2024.
• Colonization of Extramammary Sites with Mastitis-Associated S. aureus Strains in Dairy Goats. Pathogens, 2023.
• Occurrence of Clinical and Subclinical Mastitis and Associated Risk Factors in Lactating Goats with Special Reference to Dry Period Infection and Teat Skin Microflora. Alexandria Journal of Veterinary Sciences, 2020.
• Gangrenous caprine coliform mastitis. Small Ruminant Research, 1994.
• Virulence factors genes of Staphylococcus spp. isolated from caprine subclinical mastitis. Microbial Pathogenesis, 2015.
• The role of intramammary pathogens in dairy goats. Livestock Production Science, 2003.
• Occurrence, pathogens and risk factors for subclinical mastitis in dairy goats. Arquivo Brasileiro De Medicina Veterinaria E Zootecnia, 2018.
• Ovine progressive pneumonia, caprine arthritis-encephalitis, and related lentiviral diseases of sheep and goats.. Veterinary Clinics of North America Food Animal Practice, 1990.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.